Comparison_NN of_IN In-House_NP and_CC Commercial_NP Slides_NP for_IN Detection_NP by_IN Immunofluorescence_NP of_IN Immunoglobulins_NP G_NP and_CC M_NP against_IN Bartonella_NP henselae_NNS and_CC Bartonella_NP quintana_NP We_PP compared_VBD the_DT sensitivities_NNS and_CC specificities_NNS of_IN indirect_JJ fluorescent_JJ antibody_NN tests_NNS developed_VBN in_IN our_PP$ laboratory_NN and_CC commercially_RB available_JJ from_IN Focus_NP Technologies_NPS (_( FT_NP ;_: formerly_RB MRL_NP Diagnostic_NP )_) for_IN detection_NN of_IN serum_NN antibodies_NNS to_TO Bartonella_NP spp._NP Serum_NP samples_NNS tested_VBD were_VBD from_IN patients_NNS with_IN culture-_NN or_CC PCR-confirmed_NP Bartonella_NP quintana_NP or_CC B._NP henselae_NNS infections_NNS causing_VBG cat_NN scratch_NN disease_NN (_( CSD_NP )_) ,_, chronic_JJ bacteremia_NN ,_, or_CC endocarditis_NN ._SENT At_IN a_DT cutoff_NN titer_NN of_IN 64_CD ,_, the_DT FT_NP test_NN had_VBD higher_JJR sensitivity_NN than_IN our_PP$ in-house_JJ test_NN in_IN detecting_VBG anti-B_NN ._SENT henselae_NNS immunoglobulin_NN G_NP (_( IgG_NP )_) antibodies_NNS in_IN CSD_JJ patients_NNS (_( 91.2_CD versus_IN 52.9_CD %_NN ;_: P_NN <_0.001). =1,024_NN were_VBD found_VBN only_RB in_IN endocarditis_NN patients_NNS and_CC not_RB in_IN CSD_JJ patients_NNS ._SENT With_IN the_DT FT_NP test_NN ,_, 19.1_CD %_NN of_IN CSD_JJ patients_NNS had_VBD titers_NNS of_IN IgG_NP against_IN B._NP henselae_NNS of_IN >=1,024_NN (_( P_NN <_0.001). =1,024_NN were_VBD present_JJ in_IN 75_CD %_NN of_IN serum_NN samples_NNS ,_, but_CC only_RB in_IN 16.7_CD %_NN of_IN serum_NN samples_NNS with_IN the_DT FT_NP test_NN (_( P_NN =_SYM 0.004_CD )_) ._SENT Since_IN each_DT test_NN has_VBZ advantages_NNS over_IN the_DT other_JJ ,_, the_DT serological_JJ diagnosis_NN of_IN Bartonella_NP infections_NNS would_MD benefit_VB if_IN both_DT tests_NNS were_VBD used_VBN concurrently_RB ._SENT There_EX are_VBP now_RB 18_CD species_NNS within_IN the_DT genus_NN Bartonella_NP ._SENT Three_NP are_VBP well-known_JJ human_JJ pathogens_NNS :_: Bartonella_NN bacilliformis_NNS ,_, B._NP quintana_NP ,_, and_CC B._NP henselae_NNS ._SENT Others_NNS have_VBP been_VBN isolated_VBN from_IN patients_NNS on_IN single_JJ occasions_NNS only_RB :_: B._NP elizabethae_NNS (_( one_CD endocarditis_NN case_NN )_) ,_, B._NP vinsonii_NP subsp_NN ._SENT berkhoffii_NP (_( one_CD endocarditis_NN case_NN )_) ,_, and_CC B._NP vinsonii_NP subsp_NN ._SENT arupensis_NN (_( one_CD case_NN of_IN bacteremia_NN )_) ._SENT B._NP clarridgeiae_NNS ,_, and_CC B._NP washoensis_NNS have_VBP been_VBN tentatively_RB associated_VBN with_IN cat_NN scratch_NN disease_NN (_( CSD_NN )_) and_CC myocarditis_NN ,_, respectively_RB ._SENT B._NP quintana_NP and_CC B._NP henselae_NNS are_VBP species_NNS of_IN worldwide_JJ distribution_NN ._SENT B._NP quintana_NP was_VBD first_RB described_VBN as_IN the_DT agent_NN of_IN trench_NN fever_NN in_IN 1918_CD and_CC is_VBZ now_RB known_VBN to_TO be_VB responsible_JJ for_IN louse-borne_JJ bacteremia_NN and_CC endocarditis_NN in_IN homeless_JJ people_NNS and_CC bacillary_JJ angiomatosis_NN in_IN AIDS_NP patients_NNS ._SENT Humans_NNS are_VBP the_DT only_RB known_VBN reservoir_NN of_IN B._NP quintana_NP ,_, and_CC transmission_NN among_IN people_NNS occurs_VBZ via_IN the_DT body_NN louse_NN ._SENT B._NP henselae_NNS ,_, a_DT species_NN first_RB recognized_VBN in_IN 1990_CD ,_, is_VBZ the_DT main_JJ etiological_JJ agent_NN of_IN CSD_NN and_CC is_VBZ also_RB responsible_JJ for_IN bacillary_JJ angiomatosis_NN and_CC peliosis_NN hepatitis_NN in_IN immunocompromised_JJ (_( mainly_RB AIDS_NP )_) patients_NNS ,_, as_RB well_RB as_IN bacteremia_NN and_CC endocarditis_NN ._SENT Cats_NNS are_VBP the_DT main_JJ reservoir_NN of_IN B._NP henselae_NNS ,_, and_CC people_NNS become_VBP infected_JJ following_VBG cat_NN scratches_NNS or_CC bites_NNS ._SENT A_DT role_NN for_IN the_DT cat_NN flea_NN (_( Ctenocephalides_NP felis_NP )_) as_IN a_DT vector_NN for_IN human_JJ transmission_NN has_VBZ been_VBN proposed_VBN ._SENT B._NP henselae_NNS comprises_VBZ two_CD distinct_JJ genotypes_NNS ,_, B._NP henselae_NNS Houston_NP and_CC B._NP henselae_NNS Marseille_NP ._SENT Diagnostic_JJ techniques_NNS for_IN infections_NNS with_IN Bartonella_NP spp._NP include_VBP culture_NN of_IN the_DT pathogen_NN ,_, molecular_JJ biology_NN techniques_NNS ,_, especially_RB PCR_NP ,_, to_TO amplify_VB Bartonella_NP sp_NN ._SENT genes_NNS ,_, and_CC serology_NN ._SENT The_DT usefulness_NN of_IN these_DT various_JJ techniques_NNS may_MD vary_VB with_IN the_DT disease_NN present_NN ._SENT Culture_NN of_IN Bartonella_NP spp._NP may_MD be_VB successful_JJ with_IN blood_NN from_IN bacteremic_JJ patients_NNS ,_, from_IN cardiac_JJ valve_NN specimens_NNS from_IN endocarditis_NN patients_NNS ,_, and_CC from_IN skin_NN ,_, lymph_NN node_NN ,_, or_CC other_JJ organ_NN biopsy_NN samples_NNS from_IN patients_NNS with_IN bacillary_JJ angiomatosis_NN ._SENT By_IN contrast_NN ,_, B._NP henselae_NNS is_VBZ only_RB rarely_RB isolated_VBN from_IN patients_NNS with_IN CSD_NN ._SENT Amplification_NN of_IN Bartonella_NP sp_NN ._SENT DNA_NN in_IN tissue_NN biopsy_NN samples_NNS is_VBZ an_DT invasive_JJ technique_NN and_CC is_VBZ mainly_RB useful_JJ for_IN patients_NNS with_IN CSD_NP (_( lymph_NN node_NN specimen_NN )_) ,_, bacillary_JJ angiomatosis_NN (_( angiomatous_JJ lesions_NNS of_IN skin_NN or_CC other_JJ organs_NNS )_) ,_, or_CC endocarditis_NN (_( cardiac_JJ valve_NN when_WRB removed_VBN )_) ._SENT Serology_NN is_VBZ the_DT only_RB noninvasive_JJ diagnostic_JJ technique_NN ,_, and_CC it_PP has_VBZ been_VBN evaluated_VBN in_IN the_DT diagnosis_NN of_IN CSD_NP ,_, bacteremia_NN ,_, and_CC endocarditis_NN ._SENT The_DT indirect_JJ fluorescent_JJ antibody_NN (_( IFA_NP )_) test_NN was_VBD first_RB described_VBN for_IN CSD_NP by_IN Regnery_NP et_FW al._FW ,_, who_WP used_VBD B._NP henselae_NNS grown_VBN in_IN Vero_NP cells_NNS as_IN antigens_NNS ._SENT It_PP remains_VBZ the_DT most_RBS frequently_RB used_VBN technique_NN ,_, and_CC many_JJ laboratories_NNS have_VBP performed_VBN Bartonella_NP serology_NN using_VBG tests_NNS developed_VBN in-house_RB ,_, with_IN reported_VBN sensitivities_NNS varying_VBG considerably_RB ,_, from_IN nearly_RB 100_CD %_NN to_TO less_JJR than_IN 30_CD %_NN ._SENT Commercially_RB prepared_VBN antigen_NN slides_NNS are_VBP now_RB available_JJ for_IN B._NP henselae_NNS and_CC B._NP quintana_NP serology_NN ,_, and_CC in_IN this_DT report_NN we_PP compare_VBP the_DT sensitivity_NN and_CC specificity_NN of_IN one_CD of_IN these_DT tests_NNS with_IN our_PP$ in-house_JJ IFA_NP test_NN ,_, which_WDT has_VBZ been_VBN used_VBN by_IN our_PP$ laboratory_NN for_IN 10_CD years_NNS ._SENT We_PP compared_VBD the_DT abilities_NNS of_IN the_DT two_CD tests_NNS to_TO detect_VB immunoglobulin_NN G_NP (_( IgG_NP )_) and_CC IgM_NP antibodies_NNS in_IN serum_NN samples_NNS from_IN patients_NNS known_VBN to_TO have_VB CSD_NNS (_( B._NP henselae_NNS )_) ,_, chronic_JJ bacteremia_NN (_( B._NP quintana_NP )_) ,_, or_CC endocarditis_NN (_( B._NP henselae_NNS and_CC B._NP quintana_NP )_) ._SENT Patients_NNS and_CC serum_NN samples_NNS ._SENT |_SYM Serum_NP samples_NNS from_IN 104_CD patients_NNS infected_VBN with_IN Bartonella_NP spp._NP ,_, comprising_VBG CSD_JJ patients_NNS (_( n_NN =_SYM 68_CD )_) ,_, patients_NNS with_IN endocarditis_NN (_( n_NN =17_NNS ;_: 5_CD patients_NNS with_IN B._NP henselae_NNS endocarditis_NN and_CC 12_CD with_IN B._NP quintana_NP endocarditis_NN )_) ,_, and_CC homeless_JJ people_NNS (_( n_NN =_SYM 19_CD )_) with_IN chronic_JJ B._NP quintana_NN bacteremia_NN but_CC without_IN endocarditis_NN ,_, were_VBD used_VBN in_IN the_DT study_NN ._SENT Diagnoses_NNS of_IN CSD_NP were_VBD based_VBN on_IN PCR_NP amplification_NN of_IN B._NP henselae_NNS DNA_NN from_IN lymph_NN node_NN samples_NNS of_IN patients_NNS with_IN regional_JJ lymphadenopathy_NN and_CC close_JJ contact_NN with_IN cats_NNS ._SENT Bartonella_NP endocarditis_NN was_VBD diagnosed_VBN by_IN positive_JJ blood_NN cultures_NNS or_CC PCR_NP amplification_NN of_IN DNA_NN of_IN the_DT organism_NN from_IN valve_NN samples_NNS ._SENT Diagnoses_NNS of_IN B._NP quintana_NP bacteremia_NN for_IN the_DT 19_CD homeless_JJ patients_NNS were_VBD based_VBN on_IN blood_NN culture_NN results_NNS ._SENT Controls_NNS included_VBD 40_CD apparently_RB healthy_JJ blood_NN donors_NNS (_( group_NN A_NP )_) ,_, 10_CD patients_NNS initially_RB thought_VBD to_TO have_VB CSD_NNS because_IN of_IN lymphadenopathy_NN but_CC later_RBR ,_, by_IN culture_NN ,_, found_VBD to_TO have_VB tuberculosis_NN (_( group_NN B_NP )_) ,_, and_CC 35_CD patients_NNS who_WP were_VBD seropositive_JJ for_IN bacterial_JJ or_CC viral_JJ diseases_NNS not_RB related_VBN to_TO Bartonella_NP species_NNS and_CC for_IN whom_WP stored_VBD serum_NN samples_NNS were_VBD available_JJ (_( group_NN C_NP )_) ._SENT Group_NP C_NP included_VBD patients_NNS seropositive_JJ for_IN cytomegalovirus_NN ,_, Epstein-Barr_NP virus_NN ,_, hepatitis_NP B_NP virus_NN ,_, human_JJ immunodeficiency_NN virus_NN ,_, acute_JJ Q_NP fever_NN ,_, chronic_JJ Q_NP fever_NN ,_, or_CC Mediterranean_JJ spotted_JJ fever_NN caused_VBN by_IN Rickettsia_NP conorii_NP ._SENT Immunofluorescence_NN assays_NNS ._SENT |_SYM All_DT serum_NN samples_NNS were_VBD examined_VBN by_IN IFA_NP for_IN the_DT presence_NN of_IN antibodies_NNS to_TO B._NP quintana_NP and_CC B._NP henselae_NNS ._SENT For_IN antigens_NNS we_PP used_VBD either_CC our_PP$ slides_NNS prepared_VBN in-house_JJ or_CC commercial_JJ slides_NNS from_IN Focus_NP Technologies_NPS (_( FT_NP )_) ,_, Cypress_NP ,_, Calif._NP (_( distributed_VBN in_IN France_NP by_IN Eurobio_NP ,_, Paris_NP ,_, France_NP )_) ._SENT We_PP prepared_VBD in-house_JJ slides_NNS by_IN using_VBG B._NP henselae_NNS strain_VBP Houston-1_NP or_CC B._NP quintana_NP strain_NN Oklahoma_NP as_IN the_DT antigen_NN ,_, as_RB previously_RB described_VBN ._SENT Briefly_RB ,_, bacteria_NNS were_VBD grown_VBN in_IN the_DT human_JJ endothelial_JJ cell_NN line_NN ECV_NP 304_CD for_IN 2_CD weeks_NNS before_IN infected_JJ cells_NNS were_VBD recovered_VBN and_CC lysed_VBN by_IN sonication_NN ._SENT Cell_NN suspensions_NNS were_VBD centrifuged_VBN at_IN 1,500_CD rpm_NN (_( 700_CD x_SYM g_NN )_) for_IN 10_CD min_NN to_TO remove_VB cell_NN debris_NN ,_, and_CC bacteria_NNS were_VBD purified_VBN by_IN using_VBG a_DT sucrose_NN gradient_NN (_( phosphate-buffered_JJ saline_NN [_SYM PBS_NP ]_SYM with_IN 25_CD %_NN sucrose_NN ;_: 6,000_CD x_SYM g_NN for_IN 30_CD min_NN )_) ._SENT The_DT resulting_VBG pellet_NN was_VBD washed_VBN in_IN PBS_NP twice_RB (_( 6,000_CD x_SYM g_NN for_IN 10_CD min_NN )_) ,_, and_CC purified_VBD bacteria_NNS were_VBD pelleted_VBN by_IN centrifugation_NN (_( 10,000_CD x_SYM g_NN for_IN 10_CD min_NN )_) ,_, resuspended_VBN in_IN 1_CD ml_NN of_IN 0.1_CD %_NN paraformaldehyde_NN ,_, and_CC incubated_VBN at_IN 4C_JJ for_IN 24_CD h_NN for_IN fixation_NN ._SENT The_DT bacterial_JJ suspension_NN was_VBD repelleted_VBN by_IN centrifugation_NN (_( 10,000_CD x_SYM g_NN for_IN 10_CD min_NN )_) ,_, resuspended_VBN in_IN sterile_JJ distilled_JJ water_NN ,_, and_CC stored_VBD at_IN -80C_NN before_IN use_NN ._SENT This_DT whole-cell_NN antigenic_JJ preparation_NN was_VBD plated_VBN onto_IN Dynatech_NP slides_NNS and_CC used_VBN for_IN detection_NN of_IN either_DT IgM_NP or_CC IgG_NP antibodies_NNS by_IN IFA_NP ._SENT FT_NP uses_VBZ the_DT same_JJ B._NP henselae_NNS Houston-1_NP and_CC B._NP quintana_NP Oklahoma_NP strains_NNS for_IN preparation_NN of_IN its_PP$ commercial_JJ slides_NNS ._SENT Bacteria_NNS are_VBP grown_VBN in_IN Vero_NP cells_NNS for_IN preparation_NN of_IN slides_NNS used_VBN to_TO detect_VB IgG_NP and_CC on_IN blood_NN agar_NN before_IN being_VBG harvested_VBN and_CC diluted_VBN in_IN yolk_NN sac_NN fluid_NN for_IN slides_NNS used_VBN to_TO detect_VB IgM_NP ._SENT For_IN both_CC the_DT FT_NP and_CC in-house_JJ tests_NNS ,_, IgG_NP titers_NNS of_IN >=64_NP and_CC IgM_NP titers_NNS of_IN >=20_NN were_VBD used_VBN as_IN cutoff_NN titers_NNS with_IN B._NP henselae_NNS or_CC B._NP quintana_NP antigens_NNS ._SENT Statistical_JJ analysis_NN ._SENT |_SYM Differences_NNS in_IN antibody_NN titers_NNS between_IN groups_NNS and/or_CC between_IN IFA_NP techniques_NNS were_VBD analyzed_VBN by_IN using_VBG the_DT chi2_JJ test_NN for_IN categorical_JJ variables_NNS or_CC Student_NP 's_POS t_NN test_NN for_IN continuous_JJ variables_NNS ._SENT A_DT two-sided_JJ P_NN value_NN of_IN <0.05_NN was_VBD considered_VBN significant_JJ ._SENT With_IN serum_NN samples_NNS from_IN CSD_JJ patients_NNS ,_, the_DT sensitivities_NNS of_IN the_DT in-house_JJ and_CC FT_NP tests_NNS using_VBG a_DT cutoff_NN titer_NN of_IN 64_CD for_IN detection_NN of_IN anti-B_NN ._SENT henselae_NNS IgG_NP antibodies_NNS were_VBD 52.9_CD and_CC 91.2_CD %_NN ,_, respectively_RB (_( P_NN <_SYM 0.001_CD )_) ._SENT Median_JJ IgG_NP titers_NNS were_VBD 64_CD with_IN the_DT in-house_JJ test_NN (_( range_NN ,_, <64_NN to_TO 256_CD )_) and_CC 256_CD with_IN the_DT FT_NP test_NN (_( range_NN ,_, <64_NN to_TO 1,024_CD )_) ._SENT IgM_NN antibodies_NNS were_VBD detected_VBN at_IN a_DT low_JJ titer_NN (_( i.e._FW ,_, 20_CD )_) for_IN only_RB two_CD patients_NNS with_IN the_DT in-house_JJ test_NN and_CC one_CD patient_NN with_IN the_DT FT_NP test_NN ._SENT IgG_NP antibodies_NNS cross-reacting_VBG with_IN B._NP quintana_NP were_VBD detected_VBN in_IN most_JJS of_IN the_DT serum_NN samples_NNS (_( 35_CD of_IN 36_CD [_SYM 97.2_CD %_NN ]_SYM ;_: median_JJ titer_NN ,_, 64_CD )_) from_IN CSD_JJ patients_NNS with_IN the_DT in-house_JJ test_NN ,_, but_CC in_IN only_RB one_CD serum_NN sample_NN with_IN the_DT FT_NP test_NN (_( P_NN <_0.001). =64_NN against_IN both_DT B._NP quintana_NP and_CC B._NP henselae_NNS antigens_NNS ._SENT However_RB ,_, significant_JJ differences_NNS in_IN antibody_NN titers_NNS were_VBD found_VBN between_IN the_DT in-house_JJ and_CC FT_NP tests_NNS ._SENT With_IN the_DT in-house_JJ test_NN ,_, 9_CD of_IN 12_CD (_( 75_CD %_NN )_) serum_NN samples_NNS from_IN patients_NNS with_IN B._NP quintana_NP endocarditis_NN had_VBD homologous_JJ IgG_NP titers_NNS of_IN >=1,024_NN ,_, whereas_IN such_JJ high_JJ titers_NNS were_VBD present_JJ in_IN only_RB 2_CD of_IN 12_CD (_( 16.7_CD %_NN )_) patients_NNS with_IN the_DT FT_NP test_NN (_( P_NN =_SYM 0.004_CD )_) ._SENT Also_RB ,_, median_JJ homologous_JJ IgG_NP titers_NNS in_IN serum_NN samples_NNS from_IN B._NP quintana_NP endocarditis_NN patients_NNS were_VBD 1,024_CD with_IN the_DT in-house_JJ test_NN but_CC only_RB 256_CD with_IN the_DT FT_NP test_NN (_( P_NN <_0.01) =1,024_NN with_IN both_DT tests_NNS (_( range_NN ,_, 1,024_CD to_TO 4,096_CD ;_: median_JJ titers_NNS of_IN 2,048_CD and_CC 1,024_CD with_IN the_DT in-house_JJ and_CC FT_NP tests_NNS ,_, respectively_RB )_) ._SENT Most_JJS of_IN them_PP had_VBD IgG_NP antibodies_NNS which_WDT cross-reacted_VBD with_IN the_DT B._NP quintana_NN antigen_NN ,_, albeit_IN at_IN lower_JJR titers_NNS (_( median_JJ titers_NNS of_IN 512_CD and_CC 256_CD with_IN the_DT in-house_JJ and_CC FT_NP tests_NNS ,_, respectively_RB )_) ._SENT No_DT antibodies_NNS to_TO B._NP quintana_NP were_VBD found_VBN in_IN 2_CD of_IN 19_CD (_( 10.5_CD %_NN )_) and_CC 3_CD of_IN 19_CD (_( 15.8_CD %_NN )_) serum_NN samples_NNS from_IN homeless_JJ patients_NNS with_IN B._NP quintana_NP bacteremia_NN with_IN the_DT in-house_JJ and_CC FT_NP tests_NNS ,_, respectively_RB ._SENT For_IN the_DT remaining_VBG patients_NNS ,_, anti-B_NN ._SENT quintana_NP IgG_NP antibodies_NNS were_VBD found_VBN at_IN low_JJ titers_NNS (_( range_NN ,_, 64_CD to_TO 512_CD ;_: median_JJ ,_, 128_CD with_IN both_DT tests_NNS )_) ._SENT Cross-reacting_NN anti-B_NN ._SENT henselae_NNS IgG_NP antibodies_NNS were_VBD found_VBN for_IN most_JJS of_IN these_DT patients_NNS ,_, at_IN similar_JJ titers_NNS ._SENT The_DT two_CD bacteremic_JJ patients_NNS with_IN a_DT homologous_JJ IgG_NP titer_NN of_IN 512_CD had_VBD no_DT echocardiographic_JJ evidence_NN of_IN endocarditis_NN ._SENT None_NN of_IN the_DT 40_CD serum_NN samples_NNS from_IN blood_NN donors_NNS (_( group_NN A_NP )_) were_VBD found_VBN to_TO contain_VB antibodies_NNS to_TO B._NP quintana_NP or_CC B._NP henselae_NNS by_IN either_CC of_IN the_DT two_CD tests_NNS ._SENT Among_IN the_DT group_NN B_NN controls_NNS ,_, only_RB one_PP had_VBD an_DT IgG_NP titer_NN (_( of_IN 64_CD )_) detectable_JJ by_IN the_DT in-house_JJ test_NN ,_, while_IN with_IN the_DT FT_NP test_NN ,_, serum_NN samples_NNS from_IN this_DT and_CC two_CD additional_JJ controls_NNS had_VBD IgG_NP titers_NNS of_IN 64_CD ._SENT No_DT reactive_JJ antibodies_NNS were_VBD found_VBN for_IN the_DT 35_CD group_NN C_NP controls_VBZ when_WRB the_DT in-house_JJ test_NN was_VBD used_VBN ._SENT In_IN contrast_NN ,_, serum_NN samples_NNS from_IN 8_CD of_IN 35_CD (_( 22.8_CD %_NN )_) group_NN C_NP controls_NNS had_VBD IgG_NP titers_NNS (_( of_IN 64_CD to_TO 256_CD )_) to_TO Bartonella_NP spp._NP in_IN the_DT FT_NP test_NN ._SENT Cross-reacting_NP IgG_NP antibodies_NNS were_VBD found_VBN in_IN serum_NN samples_NNS from_IN three_CD cytomegalovirus_NN patients_NNS ,_, two_CD chronic_JJ Q_NP fever_NN patients_NNS ,_, and_CC three_CD patients_NNS with_IN Mediterranean_JJ spotted_JJ fever_NN ._SENT Thus_RB ,_, by_IN using_VBG a_DT cutoff_NN titer_NN of_IN >=64_NN ,_, the_DT specificities_NNS of_IN the_DT in-house_JJ and_CC FT_NP tests_NNS for_IN reactive_JJ IgG_NP were_VBD both_DT 100_CD %_NN for_IN blood_NN donors_NNS (_( group_NN A_NP )_) ;_: 90_CD and_CC 70_CD %_NN ,_, respectively_RB ,_, for_IN group_NN B_NN ;_: and_CC 100_CD and_CC 90_CD %_NN ,_, respectively_RB ,_, for_IN group_NN C_NP (_( P_NN =_SYM 0.002_CD )_) ._SENT For_IN all_DT 85_CD controls_NNS taken_VBN together_RB ,_, the_DT specificities_NNS of_IN the_DT FT_NP and_CC in-house_JJ tests_NNS were_VBD 87_CD and_CC 98.8_CD %_NN ,_, respectively_RB (_( P_NN =_SYM 0.002_CD )_) ._SENT To_TO ensure_VB a_DT specificity_NN of_IN >=95_JJ %_NN with_IN the_DT FT_NP test_NN ,_, a_DT titer_NN of_IN >=128_NN rather_RB than_IN >=64_NN should_MD have_VB been_VBN considered_VBN the_DT cutoff_NN ._SENT With_IN this_DT cutoff_NN titer_NN ,_, the_DT sensitivity_NN would_MD be_VB lower_JJR (_( 85.3_CD %_NN )_) for_IN CSD_JJ patients_NNS ,_, but_CC this_DT would_MD still_RB be_VB superior_JJ to_TO that_DT of_IN the_DT in-house_JJ test_NN ._SENT FIG._NN 1_CD ._SENT |_SYM Anti-B_NN ._SENT henselae_NNS Anti-B_NN ._SENT henselae_NNS IgG_NP titers_NNS in_IN CSD_JJ patients_NNS ._SENT FIG._NN 2_CD ._SENT |_SYM Homologous_NP IgG_NP titers_NNS in_IN patients_NNS with_IN B._NP quintana_NP Homologous_NP IgG_NP titers_NNS in_IN patients_NNS with_IN B._NP quintana_NP endocarditis_NN ._SENT FIG._NN 3_CD ._SENT |_SYM Anti-B_NN ._SENT quintana_NN Anti-B_NN ._SENT quintana_NP IgG_NP titers_NNS in_IN homeless_JJ patients_NNS with_IN chronic_JJ B._NP quintana_NN bacteremia_NN ._SENT Bartonella_NP serology_NN has_VBZ been_VBN performed_VBN in_IN our_PP$ laboratory_NN for_IN several_JJ years_NNS now_RB ,_, by_IN using_VBG B._NP quintana_NP or_CC B._NP henselae_NNS grown_VBN in_IN cell_NN culture_NN as_IN the_DT antigen_NN ._SENT The_DT aim_NN of_IN our_PP$ study_NN was_VBD to_TO compare_VB the_DT sensitivity_NN and_CC specificity_NN of_IN our_PP$ in-house_JJ test_NN to_TO that_DT of_IN a_DT recently_RB available_JJ commercial_JJ test_NN from_IN FT_NP ._SENT With_IN CSD_JJ patients_NNS ,_, our_PP$ results_NNS confirm_VBP the_DT previously_RB reported_VBN high_JJ sensitivity_NN of_IN the_DT FT_NP serological_JJ test_NN ,_, whereas_IN a_DT lower_JJR sensitivity_NN and_CC significantly_RB lower_RBR median_JJ IgG_NP titers_NNS were_VBD found_VBN with_IN our_PP$ in-house_JJ test_NN ._SENT Reactive_JJ IgM_NP antibodies_NNS were_VBD rarely_RB detected_VBN for_IN CSD_JJ patients_NNS by_IN either_DT test_NN ,_, and_CC these_DT antibodies_NNS would_MD thus_RB appear_VB to_TO be_VB of_IN little_JJ use_NN diagnostically_RB ,_, as_IN previously_RB mentioned_VBN ._SENT The_DT sensitivity_NN of_IN the_DT B._NP henselae_NNS IFA_NP test_NN first_RB described_VBN by_IN Regnery_NP et_FW al._FW for_IN detection_NN of_IN CSD_NP has_VBZ been_VBN reported_VBN from_IN different_JJ laboratories_NNS as_IN 32_CD %_NN to_TO 100_CD %_NN ._SENT Enzyme_NN immunoassay_NN (_( ,_, ,_, ,_, ,_, ,_, )_) and_CC Western_JJ blotting_VBG techniques_NNS have_VBP not_RB been_VBN consistently_RB superior_JJ to_TO IFA_NP for_IN the_DT diagnosis_NN of_IN CSD_NP ._SENT Several_JJ factors_NNS may_MD influence_VB the_DT apparent_JJ sensitivity_NN of_IN a_DT serological_JJ test_NN ._SENT First_RB ,_, sensitivity_NN may_MD change_VB according_VBG to_TO disease_NN case_NN definition_NN ._SENT Historically_RB ,_, a_DT CSD_JJ case_NN has_VBZ been_VBN defined_VBN as_IN the_DT combination_NN of_IN regional_JJ lymphadenopathy_NN with_IN characteristic_JJ histopathological_JJ features_NNS (_( granuloma_NN )_) ,_, the_DT presence_NN of_IN an_DT inoculation_NN skin_NN lesion_NN (_( e.g._FW ,_, cat_NN scratch_NN )_) ,_, a_DT history_NN of_IN cat_NN contact_NN ,_, a_DT positive_JJ result_NN on_IN a_DT skin_NN test_NN using_VBG an_DT antigen_NN prepared_VBN from_IN a_DT CSD_JJ lymph_NN node_NN exudate_NNS ,_, and_CC negative_JJ laboratory_NN results_NNS for_IN other_JJ causes_NNS of_IN lymphadenopathy_NN ._SENT More_RBR recently_RB ,_, less_JJR restrictive_JJ case_NN definitions_NNS have_VBP been_VBN used_VBN (_( e.g._FW ,_, regional_JJ lymphadenopathy_NN and_CC a_DT recent_JJ contact_NN with_IN a_DT cat_NN )_) ,_, since_IN the_DT skin_NN test_NN antigen_NN is_VBZ no_RB longer_RBR available_JJ and_CC lymph_NN node_NN biopsies_NNS are_VBP performed_VBN infrequently_RB ._SENT However_RB ,_, a_DT number_NN of_IN patients_NNS (_( e.g._FW ,_, 14_CD %_NN in_IN the_DT study_NN of_IN Flexman_NP et_FW al._FW )_) with_IN elevated_JJ anti-B_NN ._SENT henselae_NNS antibody_NN levels_NNS report_VBP no_DT previous_JJ contact_NN with_IN a_DT cat_NN ,_, and_CC many_JJ patients_NNS present_JJ with_IN clinically_RB atypical_JJ cases_NNS of_IN CSD_NN ._SENT Use_NN of_IN a_DT restrictive_JJ case_NN definition_NN for_IN CSD_NP may_MD erroneously_RB increase_VB the_DT sensitivity_NN of_IN a_DT serological_JJ test_NN because_IN only_JJ patients_NNS with_IN evident_JJ epidemiological_JJ and_CC clinical_JJ findings_NNS suggestive_JJ of_IN CSD_NN will_MD be_VB considered_VBN ._SENT Thus_RB ,_, in_IN a_DT series_NN of_IN 354_CD suspected_JJ cases_NNS of_IN CSD_NN where_WRB serum_NN samples_NNS were_VBD examined_VBN for_IN anti-B_NN ._SENT henselae_NNS antibodies_NNS ,_, Flexman_NP et_FW al._FW reported_VBD a_DT sensitivity_NN of_IN 18_CD %_NN (_( with_IN a_DT cutoff_NN titer_NN of_IN >=1:64_NN )_) ._SENT However_RB ,_, when_WRB only_RB the_DT 98_CD patients_NNS who_WP met_VBD the_DT clinical_JJ case_NN definition_NN of_IN CSD_NP (_( lymphadenopathy_NN and_CC recent_JJ contact_NN with_IN a_DT cat_NN )_) were_VBD considered_VBN ,_, the_DT sensitivity_NN was_VBD 54_CD %_NN ._SENT Accurate_JJ determination_NN of_IN the_DT sensitivity_NN and_CC specificity_NN of_IN a_DT serological_JJ test_NN requires_VBZ well-defined_JJ patient_JJ groups_NNS (_( infected_JJ and_CC uninfected_JJ )_) ,_, identified_VBN by_IN objective_JJ diagnostic_JJ procedures_NNS rather_RB than_IN clinical_JJ and_CC epidemiological_JJ data_NNS ._SENT In_IN a_DT few_JJ recent_JJ studies_NNS ,_, B._NP henselae_NNS DNA_NN amplification_NN from_IN lymph_NN node_NN biopsy_NN samples_NNS was_VBD used_VBN for_IN confirmation_NN of_IN the_DT diagnosis_NN of_IN CSD_NN in_IN a_DT portion_NN of_IN cases_NNS ._SENT Giladi_NP et_FW al._FW recently_RB evaluated_VBN an_DT enzyme_NN immunoassay_NN for_IN detection_NN of_IN anti-B_NN ._SENT henselae_NNS antibodies_NNS in_IN PCR-confirmed_JJ cases_NNS of_IN CSD_NN ._SENT We_PP report_VBP the_DT first_JJ evaluation_NN of_IN IFA_NP tests_NNS for_IN Bartonella-infected_JJ patients_NNS for_IN whom_WP diagnoses_NNS were_VBD unambiguously_RB established_VBN by_IN either_DT culture_NN or_CC DNA_NN amplification_NN using_VBG PCR_NP ._SENT Diagnoses_NNS of_IN diseases_NNS not_RB related_VBN to_TO Bartonella_NP spp._NP in_IN control_NN patients_NNS were_VBD also_RB carefully_RB documented_VBN The_DT apparent_JJ sensitivity_NN of_IN a_DT serological_JJ test_NN may_MD also_RB be_VB greatly_RB influenced_VBN by_IN the_DT cutoff_NN values_NNS used_VBD ._SENT Usually_RB ,_, cutoff_NN titers_NNS are_VBP chosen_VBN to_TO obtain_VB a_DT specificity_NN of_IN at_IN least_JJS 95_CD %_NN in_IN control_NN patients_NNS ._SENT The_DT control_NN groups_NNS are_VBP usually_RB composed_VBN of_IN a_DT mixture_NN of_IN apparently_RB healthy_JJ blood_NN donors_NNS and_CC patients_NNS with_IN a_DT disease_NN distinct_JJ from_IN the_DT disease_NN being_VBG tested_VBN ._SENT Using_VBG an_DT IFA_NP test_NN for_IN detection_NN of_IN anti-B_NN ._SENT henselae_NNS IgG_NP antibodies_NNS at_IN a_DT cutoff_NN titer_NN of_IN 64_CD in_IN CSD_JJ patients_NNS ,_, Regnery_NP et_FW al._FW ,_, and_CC Zangwill_NN et_FW al._FW in_IN the_DT United_NP States_NPS ,_, reported_VBD sensitivities_NNS of_IN 88_CD and_CC 84_CD %_NN ,_, respectively_RB ,_, but_CC the_DT specificity_NN was_VBD only_RB similar90_JJ %_NN ._SENT In_IN each_DT study_NN ,_, specificity_NN was_VBD high_JJ at_IN similar99_JJ %_NN when_WRB a_DT titer_NN of_IN 512_CD was_VBD considered_VBN the_DT cutoff_NN ,_, but_CC sensitivities_NNS decreased_VBD to_TO only_RB 67_CD and_CC 64_CD %_NN ,_, respectively_RB ._SENT Bergmans_NP et_FW al._FW in_IN The_DT Netherlands_NPS reported_VBD a_DT sensitivity_NN as_IN low_JJ as_IN 31.8_CD %_NN by_IN using_VBG a_DT cutoff_NN titer_NN of_IN 512_CD ,_, which_WDT was_VBD needed_VBN to_TO obtain_VB a_DT specificity_NN of_IN >=95_JJ %_NN in_IN blood_NN donors_NNS ._SENT The_DT cutoff_NN titer_NN may_MD depend_VB on_IN the_DT seroprevalence_NN of_IN antibodies_NNS to_TO Bartonella_NP spp._NP in_IN the_DT population_NN ,_, and_CC this_DT may_MD vary_VB with_IN geographical_JJ region_NN ._SENT We_PP found_VBD a_DT specificity_NN of_IN 98.8_CD %_NN with_IN the_DT in-house_JJ test_NN but_CC only_RB 87_CD %_NN with_IN the_DT FT_NP test_NN for_IN the_DT 85_CD controls_NNS we_PP studied_VBD ._SENT With_IN the_DT FT_NP test_NN ,_, the_DT specificity_NN was_VBD only_RB 70_CD %_NN for_IN the_DT 10_CD patients_NNS with_IN tuberculous_JJ lymphadenopathy_NN ._SENT In_IN our_PP$ laboratory_NN ,_, cultures_NNS of_IN about_RB 5_CD %_NN of_IN lymph_NN node_NN biopsy_NN samples_NNS submitted_VBD yield_NN Mycobacterium_NN tuberculosis_NN ,_, while_IN Bartonella_NP spp._NP are_VBP demonstrated_VBN in_IN approximately_RB 30_CD %_NN of_IN samples_NNS by_IN culture_NN or_CC PCR_NP ._SENT A_DT highly_RB specific_JJ test_NN for_IN CSD_NN is_VBZ critical_JJ in_IN order_NN to_TO accurately_RB rule_VB out_RP other_JJ ,_, more_RBR serious_JJ diseases_NNS which_WDT may_MD present_VB as_IN chronic_JJ lymphadenopathy_NN ,_, including_VBG tuberculosis_NN or_CC lymphoma_NN ._SENT To_TO ensure_VB a_DT specificity_NN of_IN >=95_JJ %_NN with_IN the_DT FT_NP test_NN ,_, a_DT cutoff_NN titer_NN of_IN >=128_NN should_MD be_VB used_VBN instead_RB of_IN >=64_NN ._SENT It_PP is_VBZ becoming_VBG clear_JJ that_IN some_DT patients_NNS with_IN typical_JJ CSD_NNS have_VBP no_DT detectable_JJ antibodies_NNS to_TO B._NP henselae_NNS ,_, as_RB shown_VBN in_IN our_PP$ study_NN ._SENT Demers_NP et_FW al._FW reported_VBD a_DT seronegative_JJ patient_NN diagnosed_VBN by_IN culture_NN of_IN B._NP henselae_NNS from_IN a_DT lymph_NN node_NN ._SENT Serology_NN may_MD be_VB negative_JJ early_RB in_IN the_DT course_NN of_IN the_DT disease_NN ._SENT Also_RB ,_, the_DT antigenic_JJ preparation_NN used_VBN for_IN serology_NN may_MD greatly_RB influence_VB the_DT results_NNS ._SENT Low_JJ antibody_NN titers_NNS are_VBP usually_RB found_VBN when_WRB B._NP henselae_NNS grown_VBN on_IN agar_NN is_VBZ used_VBN as_IN the_DT antigen_NN rather_RB than_IN cell_NN culture-grown_JJ organisms_NNS ._SENT Poor_JJ antibody_NN responses_NNS to_TO B._NP henselae_NNS antigen_NN have_VBP also_RB been_VBN ascribed_VBN to_TO the_DT antigenic_JJ variability_NN between_IN the_DT two_CD B._NP henselae_NNS serotypes_NNS that_WDT have_VBP been_VBN described_VBN ._SENT Both_CC the_DT in-house_JJ and_CC FT_NP tests_NNS use_VBP B._NP henselae_NNS strain_VBP Houston-1_JJ grown_VBN in_IN cell_NN culture_NN as_IN the_DT antigen_NN ._SENT Discrepancies_NNS between_IN the_DT two_CD techniques_NNS with_IN CSD_NN and_CC endocarditis_NN patients_NNS may_MD be_VB explained_VBN by_IN the_DT mode_NN of_IN antigen_NN preparation_NN and_CC conservation_NN ,_, as_IN this_DT may_MD greatly_RB influence_VB antigenic-epitope_NN recognition_NN by_IN serum_NN antibodies_NNS ._SENT Finally_RB ,_, other_JJ Bartonella_NP species_NNS (_( including_VBG B._NP clarridgeiae_NNS )_) may_MD cause_VB CSD_NN ,_, and_CC antibodies_NNS to_TO these_DT organisms_NNS do_VBP not_RB react_VB with_IN B._NP henselae_NNS ._SENT This_DT was_VBD not_RB the_DT case_NN in_IN our_PP$ study_NN ,_, since_IN our_PP$ PCR_NP results_NNS showed_VBD that_IN all_DT CSD_JJ patients_NNS were_VBD infected_VBN with_IN B._NP henselae_NNS ,_, and_CC the_DT lack_NN of_IN detectable_JJ antibodies_NNS to_TO B._NP henselae_NNS in_IN some_DT patients_NNS may_MD then_RB truly_RB represent_VB a_DT lack_NN of_IN sensitivity_NN in_IN the_DT serological_JJ tests_NNS ._SENT For_IN homeless_JJ patients_NNS with_IN chronic_JJ B._NP quintana_NN bacteremia_NN ,_, both_CC the_DT FT_NP and_CC in-house_JJ tests_NNS detected_VBD only_RB low_JJ levels_NNS of_IN homologous_JJ IgG_NP antibodies_NNS ,_, and_CC both_DT failed_VBD to_TO detect_VB any_DT reactive_JJ antibodies_NNS in_IN many_JJ patients_NNS with_IN culture-positive_JJ B._NP quintana_NN bacteremia_NN ._SENT There_EX are_VBP few_JJ serological_JJ data_NNS on_IN B._NP quintana_NP infections_NNS ._SENT Although_IN two_CD large_JJ epidemics_NNS of_IN trench_NN fever_NN occurred_VBD during_IN the_DT first_JJ and_CC second_JJ World_NP Wars_NPS ,_, B._NP quintana_NP had_VBD not_RB yet_RB been_VBN cultured_VBN and_CC serology_NN was_VBD unavailable_JJ ._SENT More_RBR recently_RB ,_, data_NNS from_IN homeless_JJ people_NNS with_IN B._NP quintana_NP infections_NNS indicate_VBP that_IN most_JJS suffer_VBP from_IN chronic_JJ ,_, intermittent_JJ bacteremia_NN and_CC that_DT many_JJ do_VBP not_RB have_VB detectable_JJ antibodies_NNS to_TO B._NP quintana_NN when_WRB infections_NNS are_VBP diagnosed_VBN ._SENT The_DT in-house_JJ and_CC FT_NP tests_NNS both_CC detected_VBD homologous_JJ antibodies_NNS in_IN patients_NNS with_IN B._NP henselae_NNS endocarditis_NN ._SENT However_RB ,_, only_JJ IgG_NP titers_NNS obtained_VBN with_IN the_DT in-house_JJ technique_NN allowed_VBD efficient_JJ discrimination_NN between_IN endocarditis_NN patients_NNS and_CC those_DT with_IN CSD_NP ._SENT All_DT B._NP henselae_NN endocarditis_NN patients_NNS presented_VBN with_IN homologous_JJ IgG_NP titers_NNS of_IN >=1,024_NN ,_, whatever_WDT the_DT technique_NN used_VBD ._SENT In_IN contrast_NN ,_, none_NN of_IN the_DT CSD_JJ patients_NNS presented_VBN with_IN IgG_NP titers_NNS of_IN >=1,024_NN with_IN the_DT in-house_JJ technique_NN ,_, whereas_IN 13_CD of_IN 68_CD (_( 19.1_CD %_NN )_) had_VBD IgG_NP titers_NNS of_IN >=1,024_NN with_IN the_DT FT_NP technique_NN (_( P_NN <_0.001). =1,024_NN with_IN the_DT in-house_JJ technique_NN was_VBD 100_CD %_NN predictive_JJ of_IN endocarditis_NN ,_, which_WDT is_VBZ in_IN accordance_NN with_IN previous_JJ reports_NNS from_IN our_PP$ laboratory_NN ._SENT The_DT in-house_JJ technique_NN was_VBD more_RBR effective_JJ than_IN the_DT FT_NP technique_NN in_IN detecting_VBG homologous_JJ IgG_NP antibodies_NNS in_IN serum_NN samples_NNS from_IN homeless_JJ patients_NNS with_IN B._NP quintana_NP endocarditis_NN ._SENT The_DT strain_NN of_IN B._NP quintana_NP and_CC the_DT number_NN of_IN passages_NNS in_IN culture_NN have_VBP previously_RB been_VBN reported_VBN to_TO influence_VB seroreactivity_NN ._SENT The_DT FT_NP and_CC in-house_JJ techniques_NNS use_VBP the_DT same_JJ B._NP quintana_NP Oklahoma_NP strain_NN ,_, grown_VBN in_IN cell_NN cultures_NNS ._SENT The_DT use_NN of_IN a_DT cell_NN culture-_NN rather_RB than_IN an_DT agar-grown_JJ antigen_NN may_MD favor_VB the_DT detection_NN of_IN specific_JJ antibodies_NNS ,_, as_RB previously_RB described_VBN for_IN B._NP henselae_NNS ._SENT With_IN the_DT in-house_JJ test_NN ,_, a_DT homologous_JJ IgG_NP titer_NN of_IN >=1,024_NN was_VBD 100_CD %_NN predictive_JJ of_IN B._NP quintana_NP endocarditis_NN ._SENT Many_JJ B._NP quintana_NN endocarditis_NN patients_NNS ,_, however_RB ,_, presented_VBN with_IN lower_JJR IgG_NP titers_NNS ,_, and_CC titers_NNS of_IN 256_CD or_CC 512_CD were_VBD found_VBN in_IN 5_CD of_IN 12_CD (_( 41.6_CD %_NN )_) endocarditis_NN patients_NNS ._SENT Such_JJ titers_NNS were_VBD also_RB found_VBN in_IN 7_CD of_IN 19_CD (_( 36.8_CD %_NN )_) homeless_JJ people_NNS with_IN chronic_JJ bacteremia_NN but_CC with_IN no_DT endocarditis_NN ._SENT These_DT two_CD groups_NNS of_IN patients_NNS ,_, then_RB ,_, could_MD not_RB be_VB reliably_RB differentiated_VBN by_IN using_VBG IgG_NP titers_NNS to_TO B._NP quintana_NP ._SENT Cross-reactions_NNS have_VBP been_VBN described_VBN between_IN various_JJ Bartonella_NP spp._NP and_CC with_IN Chlamydia_NP trachomatis_NN ,_, Coxiella_NP burnetii_NP ,_, and_CC many_JJ other_JJ species_NNS ,_, including_VBG Rickettsia_NP rickettsii_NP ,_, Ehrlichia_NP chaffeensis_NN ,_, Treponema_NP pallidum_NP ,_, Francisella_NP tularensis_NN ,_, and_CC Mycoplasma_NP pneumoniae_NNS ._SENT Cross-reactivity_NN of_IN serum_NN samples_NNS containing_VBG IgM_NP antibodies_NNS directed_VBN at_IN Epstein-Barr_NP virus_NN capsid_NN antigen_NN has_VBZ also_RB been_VBN reported_VBN ._SENT The_DT cross-reactivity_NN between_IN Bartonella_NP sp_NN ._SENT and_CC Chlamydia_NP sp_NN ._SENT antigens_NNS has_VBZ been_VBN particularly_RB troublesome_JJ ,_, and_CC endocarditis_NN supposedly_RB due_JJ to_TO a_DT Chlamydia_NP sp_NN ._SENT on_IN the_DT basis_NN of_IN serology_NN has_VBZ later_RBR been_VBN shown_VBN to_TO be_VB due_JJ to_TO a_DT Bartonella_NP sp_NN ._SENT ._SENT The_DT possibility_NN of_IN cross-reactions_NNS interfering_VBG with_IN the_DT serological_JJ diagnosis_NN of_IN Bartonella_NP endocarditis_NN is_VBZ removed_VBN if_IN all_DT suspect_JJ serum_NN samples_NNS are_VBP also_RB tested_VBN for_IN antibodies_NNS to_TO C._NP burnetii_NP and_CC Chlamydia_NP spp._NP In_IN conclusion_NN ,_, our_PP$ study_NN has_VBZ shown_VBN the_DT high_JJ sensitivity_NN of_IN the_DT FT_NP test_NN in_IN detecting_VBG IgG_NP against_IN B._NP henselae_NNS in_IN CSD_JJ patients_NNS ._SENT It_PP should_MD ,_, however_RB ,_, be_VB used_VBN with_IN a_DT cutoff_NN titer_NN of_IN 128_CD to_TO raise_VB the_DT specificity_NN of_IN the_DT test_NN to_TO >=95_JJ %_NN ._SENT Highly_RB specific_JJ tests_NNS are_VBP essential_JJ for_IN CSD_NP ,_, because_IN a_DT misdiagnosis_NN may_MD delay_VB the_DT detection_NN of_IN more_JJR serious_JJ conditions_NNS (_( e.g._FW ,_, lymphoma_NN )_) ._SENT Our_PP$ in-house_JJ test_NN had_VBD an_DT advantage_NN over_IN the_DT FT_NP test_NN in_IN that_WDT it_PP allowed_VBD CSD_JJ patients_NNS to_TO be_VB reliably_RB differentiated_VBN from_IN those_DT with_IN B._NP henselae_NNS endocarditis_NN ._SENT An_DT IgG_NP titer_NN of_IN >=1,024_NN was_VBD 100_CD %_NN predictive_JJ of_IN B._NP henselae_NNS endocarditis_NN ._SENT Our_PP$ in-house_JJ test_NN was_VBD also_RB more_RBR effective_JJ than_IN the_DT FT_NP test_NN at_IN detecting_VBG antibodies_NNS to_TO B._NP quintana_NN in_IN homeless_JJ patients_NNS ,_, especially_RB those_DT with_IN endocarditis_NN ._SENT An_DT anti-B_NN ._SENT quintana_NP IgG_NP titer_NN of_IN >=1,024_NN was_VBD 100_CD %_NN predictive_JJ of_IN endocarditis_NN ,_, although_IN many_JJ patients_NNS with_IN endocarditis_NN presented_VBN with_IN lower_JJR antibody_NN levels_NNS ._SENT Since_IN both_DT tests_NNS have_VBP advantages_NNS ,_, concurrent_JJ use_NN of_IN both_DT tests_NNS should_MD be_VB considered_VBN in_IN order_NN to_TO improve_VB the_DT diagnosis_NN of_IN B._NP henselae_NNS and_CC B._NP quintana_NP infections_NNS ._SENT 